文献速递产科母胎医学

实施17α-羟孕酮己酸酯预防复发性早产:定义、障碍与后续步骤

Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
PubMed 文献 · Obstet Gynecol · 2016-01-01

美国每年有超过50万新生儿在37周前出生,有早产史的女性复发风险高。每周注射17α-羟孕酮己酸酯可降低复发性早产风险,推荐用于有自发性单胎早产史的单胎妊娠女性,最早从16周开始。本文定义了17α-羟孕酮己酸酯的人群覆盖率,并描述了获得完整疗程需经历的步骤及提高覆盖率的潜在解决方案。

要点

  • 17α-羟孕酮己酸酯推荐用于有自发性单胎早产史的单胎妊娠女性,最早从16周开始每周注射。
  • 人群覆盖率指符合条件(既往自发性单胎早产)的女性中实际接受干预的比例。
  • 获得完整疗程需经历多个步骤:及早产检、识别合格、提供、接受并坚持每周用药。

核心结论

  • 17α-羟孕酮己酸酯可降低复发性早产风险,推荐用于有自发性单胎早产史的单胎妊娠女性,最早从16周开始。
  • 人群覆盖率是衡量公共卫生项目效果的常用指标,定义为符合条件女性中实际接受干预的比例。
  • 获得完整疗程需经历一系列步骤,本文描述了这些步骤及提高覆盖率的潜在解决方案。

研究设计与样本

  • 本文为综述,描述实施17α-羟孕酮己酸酯预防复发性早产的定義、障碍与后续步骤。

主要发现

  • 美国每年有超过50万新生儿在37周前出生。
  • 有早产史的女性复发风险高。
  • 每周注射17α-羟孕酮己酸酯可降低复发性早产风险。
  • 获得完整疗程需经历及早产检、识别合格、提供、接受并坚持每周用药等步骤。

关键数值与推荐

  • 推荐从最早16周开始每周注射17α-羟孕酮己酸酯,用于有自发性单胎早产史的单胎妊娠女性。
  • 人群覆盖率定义为符合条件(既往妊娠并发自发性单胎早产)的女性中实际接受干预的比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Each year in the United States, more than 500,000 neonates are born before 37 weeks of gestation. Women who have experienced a previous preterm birth are at high risk of recurrence. A weekly prenatal injection of 17α-hydroxyprogesterone caproate decreases the risk of recurrent preterm birth and is recommended from as early as 16 weeks of gestation in women carrying singleton pregnancies who have a history of spontaneous singleton preterm birth. A commonly used metric for public health program effectiveness is population coverage of an intervention. In the case of 17α-hydroxyprogesterone caproate, population coverage can be defined as the proportion of women who are eligible for 17α-hydroxyprogesterone caproate (ie, previous pregnancy complicated by spontaneous singleton preterm birth) who actually receive the intervention. To receive a full course of 17α-hydroxyprogesterone caproate, women must negotiate a complex series of steps that includes presenting early for prenatal care, being identified as eligible for 17α-hydroxyprogesterone caproate, being offered 17α-hydroxyprogesterone caproate, accepting 17α-hydroxyprogesterone caproate, and adhering to the weekly 17α-hydroxyprogesterone caproate dose schedule. We describe this series of steps as well potential solutions to increase 17α-hydroxyprogesterone caproate coverage.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Stringer EM, Vladutiu CJ, Batra P, et al. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps. Obstet Gynecol. 2016. PMID: 27824772. doi:10.1097/AOG.0000000000001738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。